Japan must be mindful of credit rating downgrade risk, bank lobby head says
Japanese government bond (JGB) yields rose to multi-decade highs this week on market expectations that a strong performance by opposition parties calling for big spending and tax cuts could lead to an increase in Japan's already huge debt-pile.
Junichi Hanzawa, chairman of the Japanese Bankers Association, said the recent rise in bond yields likely reflected investors' anxiety over the market outlook.
"If debt expansion runs out of control, it could become difficult for the government to smoothly sell bonds in the market" as the balance of Japan's public debt is already extremely high, Hanzawa told a news conference on Thursday.
"If this happens, we must be mindful of the risk of a JGB credit rating downgrade," he said.
Recent media polls showed Prime Minister Shigeru Ishiba's ruling coalition could lose its majority in the upper house election.
Such an outcome could force Ishiba to abandon his hawkish fiscal tilt, boost spending and heed opposition calls to cut Japan's sales tax rate, analysts say.
Moody's Ratings has said an increase in tax cut pressure could be negative for Japan's rating depending on the size and duration of the cut. It rates Japan A1, the fifth-highest level.
A credit rating downgrade could trigger a triple selling of JGBs, yen and Japanese stocks - and boost the cost of dollar funding for Japanese banks.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Finextra
an hour ago
- Finextra
India's Esaf Bank selects SugarCRM for relationship management
ESAF Small Finance Bank (ESAF SFB) has selected SugarCRM as a key technology partner to support its digital transformation as part of ESAF Bank's multi-year StratoNeXt initiative. 0 ESAF Bank will use the platform to deliver a more connected, modern banking experience to its more than 9 million customers. With 787 branches across India's 26 States, ESAF Bank is modernizing its core systems to enhance service delivery, ensure compliance with evolving regulations, and move toward fully digital, data-driven operations. Sugar will be the central engine for ESAF Bank's unified customer experience strategy, supporting real-time engagement, deep personalization and seamless service across all touchpoints - delivering a single source of truth across departments and systems for real-time visibility into every customer relationship. The platform will integrate with over 15 internal systems, including core banking, loan origination, digital onboarding, contact center, and marketing tools. By bringing together sales and service, ESAF Bank can better manage customer inquiries and leads - whether they come from a branch, website, call center, or mobile app - resulting in faster and more consistent customer responses. As part of ESAF Bank's regulated processes, Sugar will also support the creation of Customer Information Files (CIFs) directly within the system, giving each customer a unique ID that links all their accounts - a key part of ensuring data integrity across the bank. To further meet regulatory requirements, Sugar will be hosted locally at ESAF Bank's data centers in India, ensuring full compliance with Reserve Bank of India (RBI) data security regulations. 'At ESAF Bank, our mission is to serve customers with care, precision, and speed - especially in communities where financial access is limited,' said George K. John, Executive Director, ESAF Small Finance Bank. 'SugarCRM will give our teams a full, real-time view of every customer and every interaction. It's a critical step toward building a digitally connected, customer-focused bank that's scalable, compliant, and ready for the future. Apart from efficiently catering to customer needs, this will help us strengthen customer experience and optimize our marketing spend.' 'Customer experience is a crucial strategic differentiator for banks by making interactions with customers faster and easier and more personalized,' said SugarCRM's James Frampton, Chief Revenue Officer. 'Sugar will help ESAF Bank bring together data from branches, online banking, mobile apps, and other systems. This will make it easier to resolve issues quickly, tailor service to each customer, and stay compliant with regulations. We're proud to play a central role in ESAF Bank's transformation.'
The Independent
an hour ago
- The Independent
China summons Nvidia over 'backdoor safety risks' in H20 chips
China 's cyberspace regulators on Thursday summoned Nvidia over security concerns that its H20 chips can be tracked and turned off remotely, the Cyberspace Administration of China said on its website. In the meeting, Chinese regulators demanded that the U.S. chip company provide explanations on 'backdoor safety risks' of its H20 chips to be sold in China and submit relevant materials, the office said. ' Cybersecurity is critically important to us. NVIDIA does not have 'backdoors' in our chips that would give anyone a remote way to access or control them,' an Nvidia spokesperson said in a statement to AP. It came just about two weeks after the Trump administration lifted the block on the computing chips and allowed Nvidia to resume sales of H20 chips to the Chinese market. Jensen Huang, chief executive of Nvidia, made the announcement with fanfare when he was in Beijing earlier this month. The latest episode appears to be another turbulence in the tech rivalry between the United States and China, which have left businesses in both countries tussling with governments over market access and national security concerns. Any safety concern by Beijing could jeopardize the sale of H20 chips in China. Citing unnamed U.S. AI experts, the Chinese regulators said Nvidia has developed mature technology to track, locate and remotely disable its computing chips. The regulators summoned Nvidia to 'safeguard the cybersecurity and data security of Chinese users,' in accordance with Chinese laws, the statement said. The statement also referred to a call by U.S. lawmakers to require tracking and locating capabilities on U.S. advanced chips sold overseas. In May, Rep. Bill Huizenga, R.-Michigan, and Rep. Bill Foster, D.-Illinois, introduced the Chip Security Act that would require high-end chips to be equipped with 'security mechanisms' to detect 'smuggling or exploitation.' The bill has not moved through Congress since its introduction. Foster, a trained physicist, then said, 'I know that we have the technical tools to prevent powerful AI technology from getting into the wrong hands.' The U.S. still bans the sale to China of the most advanced chips, which are necessary for developing artificial intelligence. Both countries aim to lead in the artificial intelligence race. The Trump administration in April blocked the sales of H20 chips, which Nvidia developed to specifically comply with U.S. restrictions for exports of AI chips to China. After the ban was lifted, Nvidia expected to sell hundreds of thousands more H20 chips in the Chinese market. But the easing of the ban has raised eyebrows on Capitol Hill. On Monday, a group of top Democratic senators, including Minority Leader Sen. Chuck Schumer, wrote to Commerce Secretary Howard Lutnick to express their 'grave concerns". While chips like the H20 have differing capabilities than the most advanced chips such as Nvidia's H100, 'they give (China) capabilities that its domestically-developed chipsets cannot,' the senators wrote. Shortly after the ban was lifted, Rep. John Moolenaar, R.-Michigan, who chairs the House Select Committee on China, objected. 'The Commerce Department made the right call in banning the H20. Now it must hold the line,' Moolenaar wrote in a letter to Lutnick. 'We can't let the CCP use American chips to train AI models that will power its military, censor its people, and undercut American innovation," Moolenaar wrote, referring to the Chinese Communist Party by its acronym.
Reuters
an hour ago
- Reuters
Biogen signals Leqembi sales gaining momentum, lifts profit forecast
July 31 (Reuters) - Biogen (BIIB.O), opens new tab raised its annual profit forecast and beat estimates for quarterly results on Thursday, as strong demand for its rare disease drugs largely countered declining sales of its older multiple sclerosis treatments. Its shares rose as much as 5.6%, with the drugmaker also topping sales estimates for its keenly-watched Alzheimer's treatment Leqembi, which has struggled with slower uptake. Global sales of Leqembi, developed with Japan's Eisai (4523.T), opens new tab, rose fourfold from a year earlier to about $160 million, surpassing analysts' estimates. A large part of the jump was driven by U.S. sales at $63 million, which also exceeded estimates of $60.5 million, according to Jefferies. "This is the first time we've seen this market grow approximately by 15% based on total new patient starts," Biogen's North America head Alisha Alaimo said on a post-earnings call with analysts. Leqembi, which sells for $26,500 annually in the U.S., had a slow start due to concerns over cost, efficacy and side effects. But Biogen said improved rates of blood tests to diagnose the memory-robbing condition have helped with the uptake. The U.S. Food and Drug Administration cleared the first blood test to diagnose Alzheimer's disease in May. Meanwhile, Biogen said it does not expect President Donald Trump's tariffs to have a material impact on its profits this year as a significant portion of its U.S. revenue comes through domestic manufacturing. It announced a $2 billion investment in its key North Carolina manufacturing facility last week. Pharmaceuticals have long been shielded from tariffs, but the Trump administration has started to include them in trade deals to spur domestic drug manufacturing. Biogen, under CEO Chris Viehbacher, has turned to deals, cost-cutting and newer drugs to address investor pressure for growth. Its rare disease portfolio – which includes genetic disorder drug Skyclarys, spinal muscular atrophy drug Spinraza and ALS drug Qalsody – brought in sales of $543 million in the second quarter, up 2% from a year earlier. Spinraza sales, however, registered an 8.5% fall, hurt by inventory drawdown outside the U.S., which Biogen expects to continue into the third quarter. On an adjusted basis, the company expects 2025 profit of between $15.50 per share and $16.00 per share, compared with its previous forecast of $14.50 to $15.50. It earned $5.47 per share in the reported quarter, beating analysts' expectations of $3.86.
